Yuelong Yang1, Yunjun Yang1, Xiaoling Wu1, Yi Pan2, Dong Zhou3, Hongdan Zhang2, Yonglu Chen1, Jiayun Zhao1, Zihua Mo1, Biao Huang4. 1. Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China. 2. Department of Radiotherapy, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. 3. Department of Neurosurgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. 4. Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China. huangbiao@gdph.org.cn.
Abstract
BACKGROUND: The Brain Tumor Reporting and Data System (BT-RADS) category 3 is suitable for identifying cases with intermediate probability of tumor recurrence that do not meet the Response Assessment in Neuro-Oncology (RANO) criteria for progression. The aim of this study was to evaluate the added value of dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC PWI) and diffusion-weighted imaging (DWI) to BT-RADS for differentiating tumor recurrence from non-recurrence in postoperative high-grade glioma (HGG) patients with category 3 lesions. METHODS: Patients with BT-RADS category 3 lesions were included. The maximal relative cerebral blood volume (rCBVmax) and the mean apparent diffusion coefficient (ADCmean) values were measured. The added value of DSC PWI and DWI to BT-RADS was evaluated by receiver operating characteristic (ROC) curve analysis. RESULTS: Fifty-one of 91 patients had tumor recurrence, and 40 patients did not. There were significant differences in rCBVmax and ADCmean between the tumor recurrence group and non-recurrence group. Compared to BT-RADS alone, the addition of DSC PWI to BT-RADS increased the area under curve (AUC) from 0.76 (95% confidence interval [CI] 0.66-0.84) to 0.90 (95% CI 0.81-0.95) for differentiating tumor recurrence from non-recurrence. The addition of DWI to BT-RADS increased the AUC from 0.76 (95% CI 0.66-0.84) to 0.88 (95% CI 0.80-0.94). The combination of BT-RADS, DSC PWI, and DWI exhibited the best diagnostic performance (AUC = 0.95; 95% CI 0.88-0.98) for differentiating tumor recurrence from non-recurrence. CONCLUSION: Adding DSC PWI and DWI to BT-RADS can significantly improve the diagnostic performance for differentiating tumor recurrence from non-recurrence in BT-RADS category 3 lesions.
BACKGROUND: The Brain Tumor Reporting and Data System (BT-RADS) category 3 is suitable for identifying cases with intermediate probability of tumor recurrence that do not meet the Response Assessment in Neuro-Oncology (RANO) criteria for progression. The aim of this study was to evaluate the added value of dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC PWI) and diffusion-weighted imaging (DWI) to BT-RADS for differentiating tumor recurrence from non-recurrence in postoperative high-grade glioma (HGG) patients with category 3 lesions. METHODS:Patients with BT-RADS category 3 lesions were included. The maximal relative cerebral blood volume (rCBVmax) and the mean apparent diffusion coefficient (ADCmean) values were measured. The added value of DSC PWI and DWI to BT-RADS was evaluated by receiver operating characteristic (ROC) curve analysis. RESULTS: Fifty-one of 91 patients had tumor recurrence, and 40 patients did not. There were significant differences in rCBVmax and ADCmean between the tumor recurrence group and non-recurrence group. Compared to BT-RADS alone, the addition of DSC PWI to BT-RADS increased the area under curve (AUC) from 0.76 (95% confidence interval [CI] 0.66-0.84) to 0.90 (95% CI 0.81-0.95) for differentiating tumor recurrence from non-recurrence. The addition of DWI to BT-RADS increased the AUC from 0.76 (95% CI 0.66-0.84) to 0.88 (95% CI 0.80-0.94). The combination of BT-RADS, DSC PWI, and DWI exhibited the best diagnostic performance (AUC = 0.95; 95% CI 0.88-0.98) for differentiating tumor recurrence from non-recurrence. CONCLUSION: Adding DSC PWI and DWI to BT-RADS can significantly improve the diagnostic performance for differentiating tumor recurrence from non-recurrence in BT-RADS category 3 lesions.
Entities:
Keywords:
Diffusion magnetic resonance imaging; High-grade glioma; Perfusion magnetic resonance imaging; Recurrence; Structured template
Authors: Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Alex Förster; Stefanie Brehmer; Marcel Seiz-Rosenhagen; Iris Mildenberger; Frank A Giordano; Holger Wenz; David Reuss; Daniel Hänggi; Christoph Groden Journal: J Neurooncol Date: 2018-12-18 Impact factor: 4.130
Authors: Brent D Weinberg; Ashwani Gore; Hui-Kuo G Shu; Jeffrey J Olson; Richard Duszak; Alfredo D Voloschin; Michael J Hoch Journal: J Am Coll Radiol Date: 2018-03-02 Impact factor: 5.532
Authors: James Y Zhang; Brent D Weinberg; Ranliang Hu; Amit Saindane; Mark Mullins; Jason Allen; Michael J Hoch Journal: Acad Radiol Date: 2019-08-27 Impact factor: 3.173
Authors: S Wang; M Martinez-Lage; Y Sakai; S Chawla; S G Kim; M Alonso-Basanta; R A Lustig; S Brem; S Mohan; R L Wolf; A Desai; H Poptani Journal: AJNR Am J Neuroradiol Date: 2015-10-08 Impact factor: 3.825
Authors: Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou Journal: Contrast Media Mol Imaging Date: 2018-12-02 Impact factor: 3.161
Authors: Matthew L White; Yan Zhang; Fang Yu; Nicole Shonka; Michele R Aizenberg; Pavani Adapa; Syed A Jaffar Kazmi Journal: PLoS One Date: 2019-03-18 Impact factor: 3.240
Authors: Rik van den Elshout; Tom W J Scheenen; Chantal M L Driessen; Robert J Smeenk; Frederick J A Meijer; Dylan Henssen Journal: Insights Imaging Date: 2022-10-04